아픽사반 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Apixaban Market size is expected to reach USD 8.47 Billion in 2034 from USD 3.71 Billion (2025) growing at a CAGR of 9.62% during 2026-2034.

The global apixaban market is experiencing strong growth due to the increasing prevalence of cardiovascular diseases and thromboembolic disorders. Apixaban, an oral anticoagulant, is widely used to prevent stroke and blood clots in patients with conditions such as atrial fibrillation and deep vein thrombosis. The growing aging population and rising awareness about anticoagulant therapies are key factors driving market expansion. Additionally, the shift toward novel oral anticoagulants over traditional therapies is supporting increased adoption.

Key growth drivers include the clinical advantages of apixaban, such as reduced risk of bleeding and no requirement for routine monitoring compared to older anticoagulants. The expansion of healthcare infrastructure and increasing access to advanced medications are also contributing to market growth. Furthermore, ongoing research and clinical trials are exploring new therapeutic applications, enhancing its market potential. Pharmaceutical companies are actively focusing on expanding their product portfolios and geographic reach.

Looking ahead, the apixaban market is expected to grow steadily with increasing demand for effective and convenient anticoagulant therapies. The development of generic versions will further improve accessibility and affordability. Emerging markets are likely to provide significant growth opportunities due to rising healthcare awareness. Additionally, continuous advancements in cardiovascular treatment and preventive care will drive long-term market expansion.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

• Capsule
• Tablets

By End User

• Hospitals
• Clinics
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• Fresenius Kabi AG, Bristol Myers Squibb Company, Yino Pharma Limited, Nanjing Jianyou Biochemical Pharmaceutical Co Ltd, Mylan NV, Eisai Co Ltd, Sanofi, Aspen Holdings, Hikma Pharmaceuticals PLC, Hebei Changshan Biochemical Pharmaceutical Co Ltd, Abbott, Pfizer Inc, F HoffmannLa Roche Ltd
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL APIXABAN MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Capsule Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Tablets Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL APIXABAN MARKET: BY END USER 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast End User
• 5.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL APIXABAN MARKET: BY REGION 2022-2034 (USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Type
  • 6.2.2 By End User
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Type
  • 6.3.2 By End User
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Type
  • 6.4.2 By End User
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Type
  • 6.5.2 By End User
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Type
  • 6.6.2 By End User
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL APIXABAN INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 Fresenius Kabi AG
  • 8.2.2 Bristol Myers Squibb Company
  • 8.2.3 Yino Pharma Limited
  • 8.2.4 Nanjing Jianyou Biochemical Pharmaceutical Co. Ltd
  • 8.2.5 Mylan N.V
  • 8.2.6 Eisai Co. Ltd
  • 8.2.7 Sanofi
  • 8.2.8 Aspen Holdings
  • 8.2.9 Hikma Pharmaceuticals PLC
  • 8.2.10 Hebei Changshan Biochemical Pharmaceutical Co. Ltd
  • 8.2.11 Abbott
  • 8.2.12 Pfizer Inc
  • 8.2.13 F. Hoffmann-La Roche Ltd